Education
About Us
Working with TipRanks
Follow Us
Tourmaline Bio (TRML)
NASDAQ:TRML
TRML Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.87 - $48.31
Previous CloseN/A
Volume43.44K
Average Volume (3M)309.52K
Market Cap
$375.66M
Enterprise Value$380.84M
Total Cash (Recent Filing)$140.73M
Total Debt (Recent Filing)$415.00K
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Mar 25, 2025EPS Estimate
-0.86Last Dividend Ex-Date
Oct 20, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-2.82
Shares Outstanding25,642,610
10 Day Avg. Volume234,984
30 Day Avg. Volume309,521
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.54K
Enterprise Value/Ebitda-5.36
Forecast
1Y Price Target
$57.25Price Target Upside290.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Tourmaline Bio News
PremiumCompany Announcements
Tourmaline Bio Updates on Clinical Progress and Outlook---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsTRML announced that the Phase 2 TRANQUILITY study of pacibekitug in ASCVD has surpassed its enrollment target, with 143 patients enrolled, indicating significant physician and patient interest in the mechanism.
Financial PositionWith over $300 million cash runway into 2027, the company is well positioned to advance its pipeline in cardiovascular inflammation, a rapidly emerging area of focus.
Product DifferentiationThe company's initial asset, pacibekitug, is a long-acting IL-6 inhibitor that has the potential to be best-in-class, given its high affinity, long half-life, and low immunogenicity.
Bears Say
Strategic DecisionsDue to the company’s prioritization of its cardiovascular programs, management has decided not to start a pivotal trial in 2H24.
---
Ownership Overview
Currently, No data available
---
TRML FAQ
What was Tourmaline Bio’s price range in the past 12 months?
Tourmaline Bio lowest stock price was $11.87 and its highest was $48.31 in the past 12 months.
What is Tourmaline Bio’s market cap?
Tourmaline Bio’s market cap is $375.66M.
When is Tourmaline Bio’s upcoming earnings report date?
Tourmaline Bio’s upcoming earnings report date is Mar 25, 2025 which is in 12 days.
How were Tourmaline Bio’s earnings last quarter?
Tourmaline Bio released its earnings results on Nov 07, 2024. The company reported -$0.78 earnings per share for the quarter, beating the consensus estimate of -$0.817 by $0.037.
Is Tourmaline Bio overvalued?
According to Wall Street analysts Tourmaline Bio’s price is currently Undervalued.
Does Tourmaline Bio pay dividends?
Tourmaline Bio pays a Notavailable dividend of $1.511 which represents an annual dividend yield of N/A. See more information on Tourmaline Bio dividends here
What is Tourmaline Bio’s EPS estimate?
Tourmaline Bio’s EPS estimate is -0.86.
How many shares outstanding does Tourmaline Bio have?
Tourmaline Bio has 25,642,610 shares outstanding.
What happened to Tourmaline Bio’s price movement after its last earnings report?
Tourmaline Bio reported an EPS of -$0.78 in its last earnings report, beating expectations of -$0.817. Following the earnings report the stock price went up 0.949%.
Which hedge fund is a major shareholder of Tourmaline Bio?
Currently, no hedge funds are holding shares in TRML
---
Tourmaline Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.25 (290.78% Upside)
$57.25 (290.78% Upside)
Hedge Fund Trend
Increased
By 23.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.0%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.93%
12-Months-Change
Fundamentals
Return on Equity
-27.54%
Trailing 12-Months
Asset Growth
117.43%
Trailing 12-Months
Company Description
Tourmaline Bio
Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders.
---
TRML Stock 12 Month Forecast
Average Price Target
$57.25
▲(290.78% Upside)
Technical Analysis
Best Analysts Covering TRML
1 Year
1 Year Success Rate
3/7 ratings generated profit
1 Year Average Return
-19.11%
reiterated a buy rating 3 months ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of -19.11% per trade.
---